Suppression of B-Raf(V600E) cancers by MAPK hyper-activation

Rawan Atiq; Rachel Hertz; Sophia Eldad; Elia Smeir; Jacob Bar-Tana

doi:10.18632/oncotarget.7909

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Suppression of B-Raf(V600E) cancers by MAPK hyper-activation

Rawan Atiq, Rachel Hertz, Sophia Eldad, Elia Smeir and Jacob Bar-Tana _

PDF | HTML | How to cite

Oncotarget. 2016; 7:18694-18704. https://doi.org/10.18632/oncotarget.7909

Metrics: PDF 1809 views | HTML 2415 views | ?

Abstract

Rawan Atiq1,*, Rachel Hertz1,*, Sophia Eldad1, Elia Smeir1, Jacob Bar-Tana1

1Department of Human Nutrition and Metabolism, Hebrew University Medical School, Jerusalem, Israel 91120

*These authors contributed equally to this work

Correspondence to:

Jacob Bar-Tana, e-mail: [email protected]

Keywords: B-Raf(V600E), MAPK, melanoma, colorectal cancer, papillary thyroid carcinoma

Received: November 22, 2015 Accepted: February 13, 2016 Published: March 04, 2016

ABSTRACT

B-Raf(V600E) activates MEK/MAPK signalling and acts as oncogenic driver of a variety of cancers, including melanoma, colorectal and papillary thyroid carcinoma. Specific B-Raf(V600E) kinase inhibitors (e.g., Vemurafenib) prove initial efficacy in melanoma followed shortly by acquired resistance, while failing in most other B-Raf(V600E) cancers due to primary resistance. Resistance is due to acquired mutations in the Ras/Raf/MEK/MAPK pathway and/or other oncogenic drivers that bypass B-Raf(V600E). Surprisingly, hyper-activation of MAPK by inhibiting its protein phosphatase 2A by a synthetic long-chain fatty acid analogue (MEDICA), results in oncogene-induced growth arrest and apoptosis of B-Raf(V600E) cancer cells. Growth arrest is accompanied by MAPK-mediated serine/threonine phosphorylation and suppression of a variety of oncogenic drivers that resist treatment by B-Raf(V600E) kinase inhibitors, including ErbB members, c-Met, IGFR, IRS, STAT3 and Akt. The combined activities of mutated B-Raf and MEDICA are required for generating hyper-activated MAPK, growth arrest and apoptosis, implying strict specificity for mutated B-Raf cancer cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7909

Publication Alerts

Research Papers:

Suppression of B-Raf(V600E) cancers by MAPK hyper-activation

Abstract